



Supplementary Figure S11. ULMS genomic risk stratification for progression-free survival (PFS). A, A 3-tier genomic risk group is proposed for PFS. PFS for 238 patients with primary ULMS from the MSK cohort with low-, intermediate- and high-risk genomic groups [co-occurrence of TP53 and ATRX mutations or co-occurrence of TP53 mutation and chr20q amplification (amp20q); intermediate risk – presence of any of the following: TP53 mutation, ATRX mutation or amp20q; low risk – lack of any of these three alterations], as well as stratification by tumor size (B), mitotic rate (C), and necrosis (D) are represented by Kaplan-Meier curves.